28 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary … with all applicable state, federal and foreign data privacy and security laws and regulations, including, without limitation, the European Union General
8-K
PCSA
Processa Pharmaceuticals Inc
8 Jan 24
Regulation FD Disclosure
4:30pm
. (“Processa”) will present at the Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco, CA at the Hilton San Francisco Union Square
8-K
EX-10.1
lpcdubyfqog f8w6bitl
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
xlig zvs0ng
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
x81lh
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
dh7fi7e
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
usyef1vteo
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
spqjzp 2vgpgjtwy
5 Oct 20
Prospectus supplement with pricing info
4:16pm